Tag: Guillain barr syndrome

Affecting an estimated 1 to 3 individuals per 100,000, Guillain-Barré syndrome (GBS) requires careful medical management, with special attention to avoiding drugs that could worsen outcomes. Critical decisions involving medication are necessary to prevent severe complications, making it essential to understand what medications should be avoided in GBS to ensure patient safety.

According to research, a significant number of people with Guillain-Barré syndrome (GBS)—between 55% and 89% in the acute setting—experience neuropathic pain, which can be severe and debilitating. For this challenging symptom, the anticonvulsant **gabapentin good for GBS** pain is often considered as a treatment option.

According to the CDC, tetanus vaccines are highly effective, providing over 95% protection for about 10 years for fully vaccinated individuals. While the vast majority of people experience no long-term issues, it is important to be aware of the extremely rare, yet serious, potential **long-term side effects of a tetanus shot**, such as certain neurological and autoimmune conditions.

Over 306 million COVID-19 vaccine doses were administered in the U.S. between January and June 2021, with neurological adverse events reported in about 0.03% of cases [1.3.2]. The question of whether the Pfizer vaccine can cause neuropathy is a subject of ongoing scientific investigation, with some rare cases reported.